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Psoriasis, an immunological skin disease, is characterized by epidermal hyperproliferation, chronic inflamma-
tion, and an accumulation of infiltrating T cells. IL-17A is a key cytokine that has a critical role in the
pathogenesis of psoriasis. Keratin 17 (K17) is strongly expressed in psoriatic lesions but not in normal skin. Thus,
K17 expression is regarded as a hallmark of psoriasis. We previously reported that the K17/T cells/cytokine
autoimmune loop was involved in psoriasis. However, the relationship between IL-17A and K17 has yet to be
determined. In the present study, IL-17A-induced K17 expression was confirmed in cultured keratinocytes in
both mRNA and protein levels. In addition, increased K17 expression was found in the epidermis of IL-17A-
injected mouse skin. The regulatory mechanism of K17 expression was further investigated. We found that both
the signal transducer and activator of transcription (STAT) 1 and STAT3 pathways were involved in the
upregulation of K17 expression induced by IL-17A, and that such regulation could be partially suppressed by
STAT1 or STAT3 small interfering RNA and inhibitor. Our data suggest that IL-17A can upregulate K17 expression
in keratinocytes in a dose-dependent manner through STAT1- and STAT3-dependent mechanisms. The results
indicate that IL-17A might be an important cytokine in the K17/T cells/cytokine autoimmune loop associated with
psoriasis.
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INTRODUCTION
Keratin 17 (K17), a myoepithelial keratin, is overexpressed in
psoriatic lesions, and is not found in healthy epidermis. Hence,
K17 is considered to be a hallmark of psoriasis (de Jong et al.,
1991). It has been shown that IFN-g can upregulate K17
expression by activating signal transducer and activator of
transcription (STAT) 1, a transcription factor (Jiang et al., 1994).
K17 may function as an autoantigen in the immunopathogen-
esis of psoriasis, which may be a major target for autoreactive
T cells (Fierlbeck et al., 1990). Some restricted T-cell epitope
regions, found on the K17 molecule, can promote the
proliferation of psoriatic T cells and induce the production of
IFN-g effectively (Shen et al., 2005). Thus, a positive-feedback
mechanism, previously described as a K17/T cell/cytokine
autoimmune loop, may exist to drive the pathogenesis of
psoriasis (Bockelmann et al., 2005; Shen et al., 2006). Recently,
the relationship between K17 overexpression and psoriasis has
captured the attention of dermatologists, but the regulation and
biological roles of K17 in psoriasis remains unknown.
Psoriasis is now believed to be a mixed Th1/Th17 cell-
mediated autoimmune disease, in which the likely induction
of IFN-g(þ ) IL-17(þ ) cells is considered to be pathogenic
(Ksatelan et al., 2004; Arican et al., 2005). IL-17A is a
cytokine produced by Th17 cells that helps to recruit
neutrophils and drive inflammatory responses (Albanesi
et al., 2000; Weaver et al., 2007). IL-17A expression is
detectable in psoriatic skin lesions and allergic contact
dermatitis, but not in normal skin (Teunissen et al., 1998;
Albanesi et al., 1999). Overexpression of IL-17A at both gene
transcript and protein levels has been observed in serum and
skin lesions of psoriatic patients, and is correlated with the
severity of the disease (Arican et al., 2005; Caproni et al.,
2009; Kagami et al., 2010). This evidence strongly suggests
that IL-17A is involved in the pathophysiology of psoriasis
(Fitch et al., 2007; van Beelen et al., 2007).
On the basis of two previously reported findings, (1) that
the K17/T cells/cytokine loop functions in the pathogenesis of
psoriasis (Shen et al., 2006), and (2) that IL-17A is a Th17-
produced cytokine that activates three signaling pathways,
which is detectable in psoriatic skin lesions, we hypothesized
that IL-17A may be a key cytokine member of the K17/T cells/
cytokine autoimmune loop and induce K17 expression by
activating signaling pathways, and therefore participate in the
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development of psoriasis. We tested this hypothesis in
the present study by observing the effect of IL-17A on the
expression of K17 in HaCaT human keratinocytes, normal
human epidermal keratinocytes (NHEKs), and mice model.
RESULTS
The upregulation of K17 expression in IL-17A-induced
keratinocytes
To determine whether IL-17A can upregulate K17 expression,
we pretreated HaCaT cells with IL-17A in different concen-
trations (10, 50, 250, or 500Uml1), and then analyzed K17
mRNA levels with real-time PCR. As expected, we found that
K17 mRNA levels increased with IL-17A concentration in a
dose-dependent manner, especially at higher concentrations
(250 and 500Uml1), as compared with the levels in
untreated cells (Figure 1a). Meanwhile, we constructed two
reporter vectors containing different regions of K17 promoter
spanning 244 to þ18 bp (DK17p1) and 686 to þ18 bp
(DK17p2). IL-17A upregulated the activity of DK17p2
promoter, whereas DK17p1 did not respond to IL-17A,
suggesting that the element in response to IL-17A is located
between 686 and 244bp of the K17 promoter (Figure 1b).
To further confirm this finding, ELISA and western blot assays
were performed to measure K17 protein expression. K17
protein expression was upregulated by IL-17A at concentra-
tions of 250Uml1 or higher. However, no significant
difference in the expression levels of K17 protein was
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Figure 1. Upregulation of keratin 17 (K17) expression in IL-17A-induced keratinocytes. (a) Real-time PCR analysis of K17 mRNA level. Data were
expressed as 2DDCT relative to untreated HaCaT cells. (b) K17 promoter activity was examined via reporter assay under the stimulation of IL-17A
(250Uml1). Filled arrows represent the K17 promoter region, the box the firefly luciferase gene. (c) ELISA analysis of K17 expression. (d) Protein
expression of K17 was examined using western blot. (e) Immunofluorescence was performed on HaCaT cells to measure K17 expression.
40-6-Diamidino-2-phenylindole staining for nuclei is blue. (f) Immunofluorescence was performed on normal human epidermal keratinocytes to
measure K17 expression. Bar¼ 30mm. Results represent mean±SEM from three independent experiments. *Po0.05 was considered significant.
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observed when the concentration of IL-17A was lower than
50Uml1 (Figure 1c and d). To characterize K17 protein
expression in IL-17A-treated HaCaT cells, we evaluated these
cells with two-color immunofluorescence. Immunostaining
revealed weak K17 signals in the cytoplasm of untreated
cells. In contrast, there was a gradual increase in the staining
intensity of intracellular K17, which was correlated with an
increasing concentration of IL-17A from 10 to 500Uml1. In
particular, HaCaT cells treated with an IL-17A concentration
of 250Uml1 were similar to control HaCaT cells treated
with IFN-g (Figure 1e). K17 expression (Figure 1f and
Supplementary Figure S4 online), as well as K6 and K16
expression (Supplementary Figure S1 online), was also found
in the cultured NHEKs treated with IL-17A (250Uml1).
Taken together, IL-17A upregulates K17 expression in
keratinocytes in a dose-dependent manner.
The effects of STAT1 and STAT3 signaling pathways on K17
expression in IL-17A-induced HaCaT cells
As K17 expression in HaCaT cells is primarily regulated by
STAT-dependent signaling pathways, phosphorylation of
STAT1 and STAT3 was observed in IL-17A-treated HaCaT
cells. The results of ELISA, western blot, and immunofluor-
escence showed that IL-17A could promote STAT1 and
STAT3 phosphorylation at a concentration of 250Uml1,
indicating an enhanced STAT1 and STAT3 activation
(Figure 2). To characterize that the signaling pathways of
IL-17A increase K17 expression in HaCaT cells, fludarabine
and piceatannol were used to selectively inhibit STAT1 and
STAT3 signaling, respectively. Preincubation of HaCaT cells
with fludarabine or piceatannol partially suppressed the
effect of IL-17A on K17 expression. K17 mRNA was then
quantified by real-time PCR (Figure 3a). These data show that
both fludarabine and piceatannol significantly reduce the
expression of K17. Next, the inhibition of K17 expression was
confirmed at the protein level by ELISA, western blot, and
immunofluorescence (Figure 3b, c and d). Taken together
with real-time PCR, fludarabine and piceatannol partially
suppressed the effect of IL-17A on K17 expression at the
mRNA and protein level. Thereafter, we knocked down the
expression of STAT1/3 via small interfering RNA (siRNA)
before IL-17 stimulation, which resulted in the same K17
expression variation as the specific inhibitors did (Figure 4).
These results indicate that activation of the STAT1 and STAT3
pathways are required for IL-17A-induced K17 expression in
HaCaT cells.
The role of p65 and p38 signaling pathways in K17 expression in
IL-17A-induced HaCaT cells
We examined the role that the p65 and p38 signaling
pathways have in IL-17A-induced K17 expression. HaCaT
cells were incubated with IL-17A at a concentration of
250Uml1 for 15, 30, or 60minutes, following which levels
of p65/p38 expression were determined by ELISA, western
blot, and Immunofluorescence analyses. As shown in
Supplementary Figure S2 online, increased phosphorylated
forms of both p65 and p38 were found in IL-17A pretreated
HaCaT cells, which indicated that p65 and p38 pathways
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Figure 2. Activation of signal transducer and activator of transcription (STAT) 1 and STAT3 signaling pathways in IL-17A-treated HaCaT cells. HaCaT
cells were stimulated with IL-17A (250Uml1) and the expression of STAT1, STAT3, phospho-STAT1, or phospho-STAT3 was tested with corresponding
antibodies. (a) Immunofluorescence staining of phospho-STAT1 and phospho-STAT3 in IL-17A-treated HaCaT cells at different time points. Note that the
signals obtained in cultures at 15, 30, and 60minutes showed a progressive increase in intensity. Bars¼30 mm. (b) Cell-based ELISA analysis revealed that
STAT1 and STAT3 pathways were markedly activated at 60minutes following IL-17A treatment. The graph shows the means of three samples and error
bars represent SEM values (*Po0.05). (c) The activation of phospho-STAT1 and phospho-STAT3 in IL-17A-treated HaCaT cells was analyzed by
western blot analysis at 60minutes following IL-17A treatment. DAPI, 40-6-diamidino-2-phenylindole.
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Figure 3. Inhibition of signal transducer and activator of transcription 1/3 (STAT1/3) pathways partially suppresses the effect of IL-17A on keratin 17 (K17)
expression via a specific inhibitor. (a) Examination of the inhibitory effect of fludarabine and piceatannol on IL-17A (250Uml1)-induced K17 mRNA
expression level with real-time PCR analysis. (b) The effects of STAT1/3 inhibitor on K17 expression were analyzed with ELISA. (c) Western blot of the inhibitory
effect of fludarabine and piceatannol on K17 expression. (d) Immunofluorescence analysis of K17 expression in fludarabine (2), piceatannol-treated (3), or
untreated HaCaT cells (1). 40-6-Diamidino-2-phenylindole staining for nuclei is blue. IL-17, HaCaT cells treated with IL-17; F-IL-17, treated with fludarabine and
IL-17; P-IL-17, treated with piceatannol and IL-17; IFN-g, treated with IFN-g; F-IFN-g, treated with fludarabine and IFN-g. *Po0.05. Bars¼ 30 mm.
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Figure 4. Inhibition of signal transducer and activator of transcription 1/3 (STAT1/3) pathways partially suppresses the effect of IL-17A on keratin 17
(K17) expression via STAT1/3 small interfering RNA (siRNA). (a) Examination of the inhibitory effect of STAT 1/3 siRNA on IL-17A (250Uml1)-induced K17
mRNA expression level with real-time PCR analysis. HaCaT cells were transfected with scrambled siRNA or STAT1/3 siRNA using Lipofectamine 2000 24hours
before undergoing a 48-hour stimulation with IL-17A or not. RNA samples were then collected to perform real-time PCR analysis (*Po0.05). (b) Western
blot analysis of the inhibitory effect of STAT1/3 siRNA on K17 expression. HaCaT cells were transfected with scrambled siRNA or STAT1/3 siRNA using
Lipofectamine 2000 24 hours before undergoing a 48-hour stimulation with IL-17A or not. Protein samples were then collected to perform western blot analysis.
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were activated by IL-17A in HaCaT cells. To further confirm
this finding, HaCaT cells were preincubated with PDTC and
SB203580, which are p65 and p38 inhibitors, respectively,
for 2 hours before IL-17A treatment. We found that pretreat-
ment with p65 and p38 inhibitors did not block increased
K17 expression induced by IL-17A at both mRNA and protein
levels (Supplementary Figure S3 online). These results suggest
that the p65 and p38 signaling pathways are not involved in
the induction of K17 expression in HaCaT cells stimulated
with IL-17A.
Epidermal proliferation and K17 expression induced by IL-17A
in vivo
We preformed additional experimentation in vivo in order to
further confirm that IL-17A can upregulate K17 expression in
keratinocytes. We examined whether IL-17A increased the
expression of K17 after IL-17A injection in mouse skin using
real-time PCR and immunohistological analysis. The expres-
sion of K17 mRNA after two injections was 8.9-fold higher
than that in the control group (Figure 5a). Hematoxylin and
eosin staining of sections from mouse ears after daily
injection for seven times showed the epidermal changes,
namely acanthosis (thickening of the spinous layer). The
mouse epidermal thickness was 87.55±15.06 mm (IL-17A
group) and 26.08±4.57 mm (phosphate-buffered saline (PBS)
group; Figure 5b). Immunofluorescence microscopy analysis
with anti-K17 antibody revealed prominent upregulation of
K17 in acanthotic mouse epidermis (Figure 5c). These results
suggest that IL-17A can also upregulate K17 expression that
may result in acanthosis in vivo.
DISCUSSION
In this study, we demonstrated that IL-17A induces K17
expression in keratinocytes in a dose-dependent manner,
which, to our knowledge, is previously unreported. K17 is a
putative major autoantigen recognized by autoreactive T
cells in psoriasis. Previous studies demonstrated that K17
shares the ALEEAN amino-acid sequence with streptococci M
protein (Sigmundsdottir et al., 1997), which has been proven
to be one of the exogenous antigens of psoriasis and is
associated with acute guttate psoriasis (Valdimarsson et al.,
1997, 2009; McFadden et al., 2009). In addition, it was
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Figure 5. Epidermal proliferation and upregulation of keratin 17 (K17) in the mouse skin induced by IL-17A. (a) Real-time PCR analysis of K17 mRNA level
after IL-17A treatment (500Uq.d.). Results represent mean±SEM from three independent experiments. (b) Hematoxylin and eosin-stained sections of
phosphate-buffered saline (PBS)- or 500U IL-17A-injected ears after daily injection for 7 days. Epidermal thickness was measured. Data are from three
experiments in five mice per groups. *Po0.05, IL-17A-injected versus PBS control. Bars¼200 mm. (c) Frozen sections of ears from PBS-injected or IL-17A-
injected mouse stained with rabbit anti-mouse K17 pAb, followed by FITC-conjugated goat anti-rabbit IgG (green). Nuclei were counterstained with 40-6-
diamidino-2-phenylindole (DAPI). Bars¼ 30mm. (d) A loop working in the pathogenic process of psoriasis.
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confirmed that the K17 molecule contains at least another
five psoriasis-related T-cell epitopes without the ALEEAN
sequence, and that these epitopes can stimulate the
proliferation of psoriatic T cells and promote the release of
IFN-g. Therefore, K17 has the ability to stimulate psoriatic T
cells, which produce high levels of IFN-g (Shen et al., 2006).
Moreover, it has been reported that K17 can promote
hyperplasia and Th1- and Th17-dominated inflammatory
responses in the epidermis (Depianto et al., 2010). Meanwhile,
it has been demonstrated that the expression of K17 can be
induced in vitro by IFN-g (Bonnekoh et al., 1995). Moreover,
K17 is the only keratin reported to be induced by IFN-g (Arican
et al., 2005; Van Beelen et al., 2007). Hence, we suggested
that a K17/T cell/cytokine autoimmune loop exists in the
psoriatic epidermis with IFN-g as one of the cytokine
members. Such an autoimmune loop may have a key role in
the maintenance, aggravation, and relapse of psoriatic lesions.
IL-17A is secreted predominantly by a special subset of
T-helper (Th) cells (CD4 cells) termed Th17 cells, which are
phenotypically and functionally distinct from Th1 cells, Th2
cells, and T-regulatory cells (Harrington et al., 2005; Park
et al., 2005; Wynn, 2005; Ivanov and Linde´n, 2007).
Atypically elevated IL-17A levels are found in skin lesions
and serum of psoriatic patients, whereas IL-17A remains at a
baseline level in normal skin and serum. It is widely accepted
that IL-17A is involved in the pathogenesis of psoriasis (Lowes
et al., 2008; Lee et al., 2010). As we have revealed that
IL-17A induces K17 expression by increasing the K17
promoter activity, it is safe to say that IL-17A may be an
additional important cytokine member in the K17/T
cell/cytokine autoimmune loop. Moreover, IL-17A has at
least one role in the pathogenesis of psoriasis as the inducer
of K17 expression (Figure 5d).
Furthermore, we investigated the mechanism of IL-17A-
induced expression of K17. Intracellular IL-17A signaling
includes at least three pathways. IL-17A can potentially
activate JAK/STAT, mitogen-activated protein kinase, and
NF-kB pathways (Gaffen, 2008; Shen and Gaffen, 2008;
Ivanov and Linde´n, 2009). In particular, IL-17A induces
tyrosine phosphorylation of STAT1, 2, 3, and 4 in U937
monocytic leukemia cells (Subramaniam et al., 1999;
Miyoshi et al., 2011). The STAT family can be activated by
the specificity of a cytokine signal at the cell surface. For
example, STAT1 is induced by IFN-g, IL-6, and epidermal
growth factor ; STAT2 by IFN-a; STAT3 by epidermal growth
factor and IL-6; and STAT4 by IL-12. As we know, IFN-g and
IL-6 induce K17 expression through the STAT1 signaling
pathway. IFN-a does not influence K17 gene expression
(Jiang et al., 1994; Komine et al., 1996). IL-12 (p35/p40) is
present during the activation of naive T cells, which are
polarized into Th1 cells through the activation of transcrip-
tion factors STAT4 and T-bet (Weaver et al., 2006). It is also
well established that members of the mitogen-activated
protein kinase family, such as c-Jun N-terminal kinase,
extracellular signal-regulated kinase, and p38, are clearly
involved in IL-17A-induced cytokine production (Kolls and
Linde´n, 2004). Analysis of psoriatic skin has shown that the
levels of p38 activity are increased, which is consistent with
the potential role that these kinases have in the development
of psoriasis (Johansen et al., 2005). NF-kB is highly activated
in inflammatory diseases such as in rheumatoid arthritis and
psoriasis, and is often used as a potential therapeutic target in
clinical applications. Antisense oligonucleotide therapy has
been used to block p65 activation, a member of NF-kB
signaling pathways, and is an effective treatment for a murine
model of colitis (Murano et al., 2000).
We examined the aforementioned signaling pathways and
found that HaCaT cells pretreated with IL-17A expressed
phosphorylated proteins of STAT1 and STAT3, whereas
untreated HaCaT cells did not. The induction of K17
expression by IL-17A was partially suppressed by STAT1- or
STAT3-specific inhibitor and siRNA, but not by p65 or p38
inhibitor. Taken together, we concluded that IL-17A upregu-
lates K17 expression by activating STAT1 and STAT3
signaling transduction pathways. However, we can see that
blocking the STAT 1/3 pathway cannot completely suppress
K17 expression induced by IL-17A. We therefore deduce that
there may be some other pathways involved in the regulation
of K17 expression induced by IL-17A, such as the c-Jun
N-terminal kinase and extracellular signal-regulated kinase
pathways, which our group is currently investigating.
Improved comprehension of the complex interplay be-
tween cytokines, their molecular signaling pathways in
affected cells, and the resulting changes in these affected
cells will make way for a better understanding of the
pathomechanisms involved in psoriasis. Future studies will
continue to investigate and profile the actions of particular
cytokines in both healthy and psoriatic keratinocytes. Our
study has demonstrated that K17 expression is induced by IL-
17A stimulation in keratinocytes via the STAT1 and STAT3
signaling pathways, and that IL-17A might be an important
cytokine in a K17/T cells/cytokine autoimmune loop in
psoriasis. Our findings help to further elucidate the molecular
and cellular mechanisms underlying the pathogenesis of
psoriasis, which provides the field with new strategies for the
treatment of this chronic disease.
MATERIALS AND METHODS
Cell cultures and IL-17A treatment
HaCaT cells were cultured in DMEM (Gibco-Invitrogen, Carlsbad, CA)
with 10% fetal bovine serum (Gibco-Invitrogen) under a humidified
atmosphere containing 5% CO2 at 37 1C. NHEKs were obtained from
skin biopsies of healthy volunteers (N¼ 6), who provided written,
informed consent. NHEKs were cultured in the serum-free medium,
keratinocyte growth medium (Gibco-Invitrogen), for at least 3–5 days.
Cells at 40–60% confluence were stimulated with IL-17A (10, 50, 250,
or 500Uml1) for 48hours, and IFN-g (Peprotech, Rocky Hill, NJ)-
treated HaCaT cells (250Uml1) were used as positive control. To
inhibit STAT1, STAT3, p65, and p38 signaling pathways, fludarabine,
piceatannol, PDTC, and SB203580 (100mM, respectively; Sigma,
St Louis, MO) were added 2hours before stimulation with IL-17A
(Peprotech), respectively.
siRNA targeting STAT1 and STAT3 were synthesized from Gene
Pharma (Shanghai, China) and dissolved in diethylpyrocarbonate-
treated H2O at a concentration of 20mmol l
1 as a stock. According
to the manufacturer’s instructions, HaCaT cells were transfected with
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plasmids or siRNAs using Lipofectamine 2000 (Invitrogen, Carlsbad,
CA) 24hours before stimulation with IL-17A.
Real-time PCR
Total cellular RNA was isolated using a Total RNA Extraction Kit
(Anmei Biologicals, Xi’an, China) following the manufacturer’s
instructions, and cDNA was synthesized with PrimeScript RT reagent
Kit (Takara, Ohtsu, Japan) according to the manufacturer’s protocol
and used as the template for quantitative PCR. Real-time PCR was
performed using SYBR Premix Ex Taq II (TaKaRa) on a Chromo4
continuous fluorescence detector with a PTC-200 DNA Engine
Cycler (Bio-Rad, Hercules, CA). The reaction components were
0.5 ml of forward and reverse primers for K17 and b-actin as an
internal control (Supplementary Table S1 online). The cycling
conditions were as follows: 95 1C for 2minutes, followed by 45
cycles of denaturation at 95 1C for 5 seconds, annealing at 60 1C for
10 seconds, and extension at 72 1C for 15 seconds. All reactions were
run in triplicates for at least three independent experiments. Relative
quantification was performed according to the DDCT method, and
results were expressed in the linear form using the formula 2DDCT.
Results were considered significant when at least a 2-fold difference
in expression levels was detected.
Plasmid construction and reporter assay
For the construction of the pGL3-DK17p1 and pGL3-DK17p2
reporter vectors, different regions of K17 promoter were amplified
by reverse transcription-PCR from the chromosome of primary
keratinocytes using the primers listed in Supplementary Table S1
online. The PCR products were digested with indicated restriction
enzymes (Takara) before being ligated into pGL3 basic vector
(Promega, Madison, WI).
HaCaT cells were seeded in 24-well plates and transfected with
1mg of pGL3-DK17p1 or pGL3-DK17p2. Cells were co-transfected
with 50 ng of pRL-TK (a plasmid constitutively expressing Renilla
luciferase; Promega) to normalize for transfection efficiency. Cells
were treated with IL-17A (250Uml1) for 24 hours, and then lysed
using passive lysis buffer and analyzed for firefly and Renilla
luciferase activities using the dual-luciferase reagent assay kit
(Promega) according to the manufacturer’s instructions. Values were
corrected for transfection efficiency and expressed as Mean±SEM
from at least three independent experiments.
ELISA
HaCaT cells were seeded into 96-well plates precoated with
10mgml1 poly-L-lysine with a cell density of 1.5 104 cells per well,
and then were cultured at 37 1C for 24hours. After induction of IL-17A
as described above, the expressions of K17, STAT1, STAT3, p65, p38,
phospho-STAT1, phospho-STAT3, phospho-p65, and phospho-p38
were determined by cell-based ELISA. In brief, after adherence of
cells, the cells were stimulated by IL-17A at concentrations of
10–500Uml1 at 37 1C for 48hours. After washing, the cells were
blocked with blocking buffer for 1hour at room temperature and then
were incubated with primary antibodies for K17, STAT1, STAT3, p65,
p38, phospho-STAT1, phospho-STAT3, phospho-p65, and phospho-
p38 (Cell Signaling Technology, Danvers, MA) at 37 1C for 1hour.
Next, the cells were washed and incubated with horseradish
peroxidase-conjugated anti-rabbit IgG (Dako Cytomation, Glostrup,
Denmark) at 37 1C for 1 hour. Subsequently, the cells were incubated
with 100ml of a developing solution for 10minutes at room
temperature. The reaction was stopped with 100ml of a stop solution
and the absorbance was measured at an optical reference wavelength
of 450nm with an ELISA reader.
Western blot
Total proteins of HaCaT cells were prepared for western blot
analysis. Briefly, 5 106 IL-17A-treated cells were harvested and
proteins from cell lysates were denatured in SDS, and 30mg of total
extracted proteins were applied per lane for 10% SDS-PAGE. After
proteins were transferred to Invitrolon PVDF membrane (Invitrogen),
nonspecific binding was blocked for 2 hours in the blocking buffer.
The membranes were incubated with specific antibodies against
b-actin (Abcam, Cambridge, UK), K6, K16 (Epitomics, Burlingame,
CA), K17, STAT1, STAT3, p65, p38, phospho-STAT1, phospho-
STAT3, phospho-p65, and phospho-p38 (Cell Signaling Technology)
overnight. Blots were washed with Tris-buffered saline Tween-20,
and then incubated with horseradish peroxidase-conjugated sec-
ondary antibodiess (Dako Cytomation) for 1 hour. Bound antibodies
were revealed using chemiluminescence reaction. The expression
amounts of K17 were quantitated using the AlphaImager Gel (Alpha
Innotech, San Leandro, CA) Imaging System.
Immunofluorescence staining and confocal microscopy
IL-17A-treated HaCaT cells and NHEKs were first fixed in acetone,
blocked with 20% goat serum, and then incubated with rabbit anti-
human K6 mAb, anti-human K16 mAb, anti-human K17 mAb, anti-
human phospho-STAT1 mAb, anti-human phospho-STAT3 mAb,
anti-human phospho-65 mAb, or anti-human phospho-p38 mAb
(Epitomics). To detect bound antibodies, CY3-labeled goat anti-
rabbit IgG (KPL, Gaithersburg, MD) was used. 40-6-Diamidino-
2-phenylindole (KPL) was used for nuclear counterstaining in
all cells. Laser scanning confocal microscopy was done using a
FV-1000/ES confocal microscope (Olympus, Tokyo, Japan).
Animal experiments of IL-17A-induced epidermal changes
Female BALB/c mice were obtained from the Department of
Laboratory Animal Medicine of the University and used at 8–10
weeks of age. We performed intradermal injection of 20 ml PBS,
either alone or containing 500U recombinant mouse IL-17A
(Peprotech), into the ears of anesthetized mice using a 30-gauge
needle daily for 2 days or 7 days. Five mice were used in each
experimental group, and each experiment was repeated at least three
times. After injection, the mice ears were collected and frozen
immediately in liquid nitrogen for RNA quantification, hematoxylin
and eosin staining, and immunofluorescence microscopy analysis.
The 4mm sections of mouse ear were fixed in 10% formalin in PBS
and stained with hematoxylin and eosin. Frozen sections of mouse ear
were prepared for immunofluorescence staining. Sections were fixed
with precooled acetone for 10minutes at room temperature, blocked
for 30minutes at room temperature with 5% goat serum in PBS, and
incubated with rabbit anti-mouse K17 pAb (Abcam) for 1 hour at room
temperature. After washing in PBS, the sections were incubated
for 30minutes at room temperature with an FITC-conjugated goat
anti-rabbit IgG (KPL), then washed in PBS and counterstained with
40-6-diamidino-2-phenylindole nuclear stain (KPL). Laser scanning
confocal microscopy was done using an FV-1000/ES confocal
microscope.
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Statistics
All statistical analyses were performed using GraphPad Prism 4.0
(GraphPad Software, San Diego, CA). Student’s t-test was used to
compare differences of K17 expression. P-values o0.05 were
considered statistically significant.
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